Humana expands Barostim therapy access via Medicare Advantage, CVRx secures national deal

Humana expands Barostim therapy access via Medicare Advantage, CVRx secures national deal
CVRx secures Humana coverage

CVRx has announced that Humana will issue a Medicare Advantage coverage policy for Barostim therapy, with the policy set to become effective on May 1, 2026.

Humana is one of the largest national health insurance companies in the U.S., operating the second largest Medicare Advantage program and covering around 5.2 million individuals. The expansion of coverage for Barostim therapy marks a significant step for CVRx, broadening access to advanced heart failure treatment options for millions across the country. Details about the implementation and rollout of the new policy are expected as the effective date approaches.

CVRx recently began enrolling patients in the BENEFIT-HF trial at North Central Heart, one of the largest cardiac device studies to date. The company previously reported that its Barostim device improved quality of life for heart failure patients, citing a case shared by Dr. Savitri Fedson in a patient outcome report highlighting the therapy's impact. These developments come as CVRx continues to advance Barostim therapy in the heart failure treatment landscape.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.
Weekly Top Bonuses
up to $2,500
deposit bonus for all clients
CLAIM BONUS
Your capital is at risk.